T2D injectables: 2. Intensifying to first injectable therapy in patients with ASCVD risk
You need to login to participate in this education.
This education is accredited: RACGP 3 CPD, ACRRM 2 CME PD.
This is one module of the T2D injectables series of education, which is also available as the 5-hour Accredited CPD Activity Rethinking first injectable therapies in type 2 diabetes: A practical approach.
In this education module, the participant will work through a case study of a type 2 diabetes patient with ASCVD risk factors. The case study uses the decision cycle from the ADA/EASD consensus guidelines for T2D, and features expert video commentary. The module also discusses patient-related concerns leading to clinical inertia, including useful management decisions when faced with this issue.
On completion of this education activity participants will be able to:
- Apply principles of patient-centred glycaemic management in type 2 diabetes to help choose a suitable first injectable therapy for a patient with uncontrolled type 2 diabetes and with a high risk of developing atherosclerotic cardiovascular disease.
- Outline Australian guidelines for managing ASCVD risk in type 2 diabetes.
- Consider how ASCVD risk influences the choice of first injectable therapy in type 2 diabetes and compare clinical effects of GLP-1 agents versus insulin in patients with high risk of ASCVD.
- Recognise patient factors associated with therapeutic inertia and delayed treatment intensification in type 2 diabetes and identify strategies for addressing these factors.
This activity is sponsored by Eli Lilly Australia.
|T2D injectables: 2 - Education|
|T2D injectables: 2 - Evaluation|